Last Posted: Nov 03, 2019
- Year in Review: Ovarian Cancer: PARP inhibitors, genetic testing, and novel combinations
I Ingram, Medpage Today, November 1, 2019 - The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
Kubelac Paul et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 24(4) 1538-1543 - PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer
NCI, October 29, 2019 - A comprehensive understanding of ovarian carcinoma survival prognosis by novel biomarkers.
Wang Y et al. European review for medical and pharmacological sciences 2019 Oct 23(19) 8257-8264 - Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
Kotsopoulos Joanne et al. Menopause (New York, N.Y.) 2019 Oct - Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
Lammert Jacqueline et al. Asia-Pacific journal of clinical oncology 2019 Oct - Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
Veneris Jennifer Taylor et al. Gynecologic oncology 2019 Oct - BRCA1/2 Genetic Testing Recommendations Still Leave Issues Unresolved
U Penn Medicine, 2019 - Beyonc's Dad Has a Mutation More African-Americans Should Be Tested For An inherited gene that can be discovered early caused Matthew Knowles?s breast cancer.
E Stallings, NY Times, October 16, 2019 - Do Women who Receive a Negative BRCA1/2 Risk Result Understand the Implications for Breast Cancer Risk?
Guan Yue et al. Public health genomics 2019 Oct 1-8
.png)
No hay comentarios:
Publicar un comentario